title: The serotype distribution among healthy carriers before vaccination is essential for predicting the impact of pneumococcal conjugate vaccine on invasive disease.
abstract: Pneumococcal conjugate vaccines (PCVs) have substantially reduced morbidity and mortality of pneumococcal disease. The impact of the 7-valent PCV on all-serotype invasive pneumococcal disease (IPD) among children was reported to vary between high-income countries. We investigate the ability to predict this heterogeneity from pre-vaccination data. We propose a parsimonious model that predicts the impact of PCVs from the odds of vaccine serotype (VT) among carriers and IPD cases in the pre-PCV period, assuming that VT are eliminated in a mature PCV programme, that full serotype replacement occurs in carriage and that invasiveness of the NVT group is unchanged. We test model performance against the reported impact of PCV7 on childhood IPD in high-income countries from a recent meta-analysis. The odds of pre-PCV7 VT IPD, PCV schedule, PCV coverage and whether a catch up campaign was used for introduction was gathered from the same analysis. We conducted a literature review and meta-analysis to obtain the odds of pre-PCV7 VT carriage in the respective settings. The model predicted the reported impact on childhood IPD of mature PCV programmes; the ratio of predicted and observed incidence risk ratios was close to 1 in all settings. In the high income settings studied differences in schedule, coverage, and catch up campaigns were not associated with the observed heterogeneity in impact of PCV7 on childhood all-serotype IPD. The pre-PCV7 proportion of VT IPD alone also had limited predictive value. The pre-PCV7 proportion of VT carriage and IPD are the main determinants for the impact of PCV7 on childhood IPD and can be combined in a simple model to provide predictions of the vaccine preventable burden of IPD.
authors: London School of Hygiene and Tropical Medicine, London, United Kingdom.
authors: Stefan
authors: S
authors: Flasche
authors: London School of Hygiene and Tropical Medicine, London, United Kingdom.
authors: Olivier
authors: O
authors: Le Polain de Waroux
authors: International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.
authors: Katherine L
authors: KL
authors: O'Brien
authors: London School of Hygiene and Tropical Medicine, London, United Kingdom.
authors: W John
authors: WJ
authors: Edmunds
mesh_terms: D002353:Carrier State / Q000453:epidemiology* / Q000276:immunology / Q000382:microbiology* / Q000517:prevention & control; D019295:Computational Biology; D000069443:Heptavalent Pneumococcal Conjugate Vaccine / Q000008:administration & dosage / Q000276:immunology; D006801:Humans; D008954:Models, Biological; D011008:Pneumococcal Infections / Q000453:epidemiology* / Q000276:immunology / Q000382:microbiology* / Q000517:prevention & control; D015203:Reproducibility of Results; D014611:Vaccination / Q000706:statistics & numerical data*
chemical_list: D000069443:Heptavalent Pneumococcal Conjugate Vaccine